Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro®

Great work using the #clotpro: The aim of the current study was to examine in vitro the impact of Idarucizumab and Andexanet alfa on blood samples collected from trauma patients.

Changes in plasma concentration and the clotting time using the DOAC-specific, viscoelastic assays ecarin-test for dabigatran and Russell’s viper venom-test for apixaban, edoxaban, and rivaroxaban, were investigated.

Find the article here https://www.mdpi.com/2077-0383/10/16/3476/htm